February 26, 2018 / 9:44 AM / 7 months ago

BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab

Feb 26 (Reuters) - Bavarian Nordic A/S:

* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS

* ‍BAVARIAN NORDIC AND ASTRAZENECA WILL CONTRIBUTE CLINICAL TRIAL MATERIAL AND PROVIDE FINANCIAL SUPPORT FOR PHASE 1/2​

* ‍NEW COLLABORATION THAT WILL INVESTIGATE CV301 AND DURVALUMAB (IMFINZI(TM))​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below